After extensive search, I think this should be CRXX.
Clues and the 3 month chart right after its IPO match with below teaser.
CRXX - Stansberry's Phase 1
===================================
Our Newest Phase 1 Pick...
A $7 Penny Stock Set to Triple?
===================================
There's another completely safe way to invest in the medical industry that few people know about...
Just like the drug distribution companies that work behind the scenes and rake in millions in profits, these companies have almost nothing to do with the FDA.
In other words, their profits – and the profits of their investors – aren't tied up in developing one new blockbuster drug. The secret to their success lies in a brand-new method of drug development called 'Combination Drugs.'
In short, it involves combining already approved prescription drugs to more effectively treat diseases. Because the ingredients in these 'combination drugs' have already been proven to work... there's very little risk involved for the company. And more importantly, there's very little cost... They don't have to spend millions of dollars finding brand-new drugs. But here's the clincher: The company can patent the new combination drug – and get exclusive rights to sell it. For you, it means just one thing: A low-risk way to make tens of thousands of dollars. For example, Pozen (POZN) – a small North Carolina-based biotech company –has developed a combination migraine drug called Trexima. Its stock has nearly tripled over the past 12 months. Orexigen Therapeutics (OREX) – a San Diego-based company – developed a combination obesity drug called Contrave. Its stock shot up almost 50% within the first month it went public. There are only a handful of publicly traded companies that focus on developing combination drugs... In fact, our Phase 1 Investor analysts Rob Fannon and Dr. George Huang recommended Pozen to subscribers last year. It's still a great company, but the price has shot up. Rob has, however, identified one completely under-the-radar company that trades for just under $7 at the moment... He believes it could easily double or triple in the coming months. On July 9, Rob and George even went to visit this tiny company in Cambridge, Massachusetts. They met with the CEO and CFO, as well as the company's top scientists.
Here's what they discovered:
The average biotech company has 1-2 drugs in its pipeline, and spends $802 million to develop one new drug. This tiny combination drug company, however, has a total of 8 drugs in its pipeline... and it only spent $34 million on R&D last year! That's why Nature magazine says, "Flying in the face of convention, a young biotech company in Boston, Massachusetts, has adopted a very different approach, and has so far been well rewarded for its efforts."
The company's investors have been well rewarded too... As you can see from the chart below, investors almost doubled their money just 3 months after the company went public.

http://www.stansberryonline.com/PRO/0707PHAALBSP/EDILH701/200707PHA-ALB-SP.html

100% correct
It looks to me as a very risky trade, it might work for the short term (before the report will be published)

Also on this report he is talking on other PBM stock which I solved
SXCI

you guys are the greatest.
I love this site.

CRD.